Desvenlafaxine

Indications

• FDA-approved only for major depressive disorder in adults, at a recommended dose of 50 mg once daily with or without food.
• Fixed-dose trials found no added antidepressant benefit above 50 mg/day, only more nausea, sweating, and treatment discontinuation.
• Off-label for generalized anxiety disorder and other anxiety conditions, extrapolating from venlafaxine rather than from its own trials.
• Off-label at 50-100 mg/day for vasomotor symptoms of menopause, an indication supported by several randomized trials.
• Off-label for neuropathic pain and fibromyalgia, where duloxetine and milnacipran hold the actual approvals and stronger evidence.
• Sometimes chosen when a patient is a CYP2D6 poor metabolizer or takes multiple interacting drugs, since it bypasses that enzyme.

Mechanism of action

• Inhibits both the serotonin and norepinephrine transporters, with a serotonin-to-norepinephrine potency ratio of roughly ten to one.
• Unlike venlafaxine, it delivers noradrenergic activity at the standard 50 mg/day dose without requiring dose escalation.
• Increased noradrenergic tone contributes to improvements in energy and concentration and to sweating and blood pressure elevation.
• It is the O-desmethyl metabolite of venlafaxine, so the two drugs share a pharmacologic profile and should never be combined.
• No meaningful muscarinic, histaminic, or alpha-adrenergic receptor blockade, so weight and sedation effects are limited.

Pharmacokinetics

• Absolute bioavailability is about 80 percent and is unaffected by food, so administration timing can follow patient preference.
• Half-life is approximately 11 hours, sufficient for once-daily extended-release dosing with steady state in four to five days.
• Metabolized primarily by UGT-mediated conjugation with only a minor CYP3A4 oxidative pathway, so CYP interactions are few.
• About 45 percent of a dose is excreted unchanged in urine, which is why renal impairment mandates explicit dose limits.
• It is not a clinically important inhibitor of CYP2D6 at 50 mg/day, though weak inhibition emerges at 100 mg/day and above.

Dosing

• The recommended dose is 50 mg PO once daily; no titration is needed and most patients never require a higher dose.
• Doses of 100, 200, and 400 mg/day were studied without added efficacy, so escalation should be reserved for clear partial response.
• In moderate renal impairment the maximum is 50 mg/day, and in severe impairment or end-stage renal disease it is 50 mg every other day.
• In moderate to severe hepatic impairment the maximum recommended dose is 100 mg/day, and escalation above 50 mg should be cautious.
• Supplied as 25, 50, and 100 mg extended-release tablets that must be swallowed whole; the inert shell may be visible in stool.
• Taper gradually when stopping, and use the 25 mg tablet for the final steps, since abrupt cessation produces venlafaxine-like withdrawal.

Adverse effects

• Nausea occurs in roughly 22 percent at 50 mg/day, usually in the first two weeks, along with dry mouth, headache, and dizziness.
• Sweating and hyperhidrosis are noradrenergically mediated, dose-related, and among the most persistent complaints over time.
• Sexual dysfunction rates rise with dose and include reduced libido, delayed ejaculation, and erectile difficulty in a minority of patients.
• Blood pressure and heart rate increase modestly and dose-dependently, so uncontrolled hypertension should be treated before starting.
• Discontinuation syndrome, hyponatremia, mydriasis with angle-closure risk, and increased bleeding are the serious prescribing issues.
• Elevated fasting cholesterol and triglycerides were seen in longer-term trials, more often at doses above 100 mg/day.

Monitoring

• Measure blood pressure at baseline, at two to four weeks, and periodically thereafter, particularly if the dose exceeds 50 mg/day.
• Assess suicidality, activation, and agitation weekly for the first four weeks and after any dose change, especially under age 25.
• Check creatinine and estimate clearance at baseline, since renal function directly determines the maximum permitted dose.
• Obtain a fasting lipid panel at baseline and annually, or sooner in patients maintained above 100 mg/day.
• Check serum sodium at baseline and within two to four weeks in older adults, diuretic users, or anyone with new confusion.

Interactions

• Contraindicated with MAOIs and within 14 days of stopping one, and with linezolid or intravenous methylene blue.
• Should never be combined with venlafaxine, since desvenlafaxine is its active metabolite and the effects are simply additive.
• Additive serotonin syndrome risk with triptans, tramadol, fentanyl, lithium, tryptophan, and St. John's wort.
• Additive hypertensive and tachycardic effects with stimulants and with other noradrenergic agents such as atomoxetine.
• Increases bleeding risk with aspirin, NSAIDs, warfarin, and direct oral anticoagulants through impaired platelet serotonin uptake.

Special populations

• Pregnancy data are more limited than for the SSRIs; late-gestation exposure carries neonatal adaptation and pulmonary hypertension risk.
• Breast milk data are sparse, with a relative infant dose estimated near 6 percent, so infant monitoring is advised if used.
• Not approved in pediatric patients, and adolescent depression trials did not demonstrate separation from placebo.
• In older adults start at 50 mg/day and check renal function first, since falls, hyponatremia, and hypertension risks all increase.
• Renal impairment is the key adjustment: 50 mg/day maximum if clearance is 30 to 50 mL/min, and every other day below 30 mL/min.

Clinical pearls

• One flat 50 mg dose works for most patients; higher doses add side effects without adding efficacy.
• Bypasses CYP2D6 entirely, which is its main advantage over venlafaxine on complex regimens.
• Renal function sets the ceiling: 50 mg every other day when clearance falls below 30 mL/min.